Atossa Therapeutics Inc (ATOS)
XMEX 
Summary
ATOS Chart
Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript
Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript
New Strong Sell Stocks for Oct. 22
ATOS, BLIN and CLTP have been added to the Zacks Rank #5 (Strong Sell) List on Oct. 22, 2025.
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Atossa Therapeutics Inc (ATOS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Atossa Therapeutics Inc ever had a stock split?
Atossa Therapeutics Inc Profile
| Biotechnology Industry | Healthcare Sector | Steven C. Quay CEO | XMEX Exchange | US04962H7044 ISIN |
| US Country | 15 Employees | - Last Dividend | 2 Feb 2026 Last Split | 8 Nov 2012 IPO Date |
Overview
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments for oncology, targeting areas of unmet medical need. Originally known as Atossa Genetics Inc., the company rebranded to Atossa Therapeutics, Inc. in January 2020, signifying a broader therapeutic focus. Founded in 2008, Atossa Therapeutics has established its headquarters in Seattle, Washington, positioning itself at the forefront of cancer therapy research. Through strategic collaborations, including a research agreement with Dana-Farber Cancer Institute, Inc., Atossa aims to advance its mission of delivering innovative treatments to patients battling cancer.
Products and Services
- Endoxifen
- AT-H201
- Immunotherapy/Chimeric Antigen Receptor Therapy Programs
- Cytokine-Coated Nanoparticles
At the core of Atossa's pipeline is Endoxifen, an active metabolite of tamoxifen, currently undergoing Phase II clinical trials. This promising compound is being explored for its potential in both the treatment and prevention of breast cancer. Endoxifen targets the estrogen receptor pathway, which is critical in the development and progression of many breast cancers. Its development underlines Atossa's commitment to addressing the pressing needs of patients who have limited treatment options.
Expanding its therapeutic reach beyond breast cancer, Atossa Therapeutics is developing AT-H201 for patients suffering from lung injury caused by cancer treatments. Recognizing the severe impact of such injuries on patients' quality of life, AT-H201 aims to provide a novel therapeutic solution to mitigate these adverse effects, thereby improving patient outcomes and treatment tolerance.
In pursuit of cutting-edge cancer therapies, Atossa is delving into the realm of immunotherapy and chimeric antigen receptor (CAR) therapy. These programs reflect the company's investment in the potential of the immune system to fight cancer more effectively. By developing treatments that can boost the body's natural defenses against cancer cells, Atossa is at the vanguard of efforts to harness the power of immunotherapy in oncology.
Under its research agreement with Dana-Farber Cancer Institute, Inc., Atossa is exploring the therapeutic potential of cytokine-coated nanoparticles for the treatment of breast cancer. This innovative approach seeks to enhance the delivery and effectiveness of cancer therapies, potentially leading to more efficient and less toxic treatments. The initiative demonstrates Atossa's dedication to pioneering advanced technologies for cancer treatment.
